Document Detail

Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
MedLine Citation:
PMID:  9350383     Owner:  NLM     Status:  MEDLINE    
Members of the new class of antimigraine compounds, 5HT1B/1D agonists, as well as ergotamine, may cause vasoconstriction through stimulation of 5HT receptors on peripheral vessels. The cardiovascular effects of 20 mg oral zolmitriptan (Zomig, formerly 311C90), 2 mg oral ergotamine and the combination were assessed in a randomized double-blind, placebo-controlled crossover study in 12 healthy subjects. Pharmacodynamic measures included oscillometric blood pressure, systolic blood pressure at the toe and arm using a strain gauge technique, stroke volume and cardiac output using bioimpedance cardiography, high-resolution ultrasound to measure brachial arterial diameter and a novel Doppler method to measure blood flow velocity. Both drugs produced small degrees of peripheral vasoconstriction, including increases in diastolic blood pressure and blood flow velocity and decreases in arterial diameter and toe-arm systolic pressure gradient. These effects were generally additive with the combination but of no clinical importance. There were no significant changes in cardiac output, stroke volume heart rate or ECG. Zolmitriptan, at eight times the likely therapeutic dose, was generally well tolerated both alone and in combination with ergotamine. Ergotamine had no clinically important effects on zolmitriptan pharmacokinetics.
R M Dixon; H B Meire; D H Evans; H Watt; N On; J Posner; P E Rolan
Related Documents :
443603 - A simple technique for measuring arterial blood pressures in conscious human subjects.
15064843 - Ankle/brachial index in the primary care setting.
8217173 - Bronchial mucus transport in chronic smokers and nonsmokers during general anesthesia.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cephalalgia : an international journal of headache     Volume:  17     ISSN:  0333-1024     ISO Abbreviation:  Cephalalgia     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-12-09     Completed Date:  1997-12-09     Revised Date:  2008-02-11    
Medline Journal Info:
Nlm Unique ID:  8200710     Medline TA:  Cephalalgia     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  639-46     Citation Subset:  IM    
Department of Clinical Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Biological Availability
Blood Pressure / drug effects
Caffeine / therapeutic use*
Cross-Over Studies
Double-Blind Method
Drug Therapy, Combination
Ergotamine / adverse effects,  pharmacokinetics,  therapeutic use*
Intestinal Absorption / drug effects
Oxazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Reference Values
Serotonin Agonists / therapeutic use*
Vasoconstrictor Agents / therapeutic use*
Reg. No./Substance:
0/Oxazoles; 0/Oxazolidinones; 0/Serotonin Agonists; 0/Tryptamines; 0/Vasoconstrictor Agents; 113-15-5/Ergotamine; 139264-17-8/zolmitriptan; 58-08-2/Caffeine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphe...
Next Document:  Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment ...